Skip to main content

The Endocrine Regulation of Blood Pressure

  • Reference work entry
  • First Online:
Principles of Endocrinology and Hormone Action

Part of the book series: Endocrinology ((ENDOCR))

  • 2830 Accesses

Abstract

Blood pressure is a vital parameter controlled by very complex mechanisms mainly involving neuronal and endocrine effectors. The sympathetic-adrenal system (SAS) and the renin-angiotensin-aldosterone system (RAAS), besides paracrine mechanisms in the vessel wall, are the main players of these complex networks that permit the maintenance of blood pressure, sufficient for the perfusion of organs and tissues. These systems regulate the cardiac pump, the circulating volume, and the peripheral resistances. They are the targets of almost all the drugs prescribed to hypertensive patients.

In addition to these major neurohormonal systems, many other factors can modulate blood pressure participating in the control of the blood volume or the peripheral resistances. These factors include, among the others, natriuretic peptides, dopamine, nitric oxide, endothelin-1, vasopressin, and cortisol.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

References

  • Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol. 2002;90:40L–8.

    Article  CAS  PubMed  Google Scholar 

  • Belloni AS, Rossi GP, Andreis PG, Neri G, Albertin G, Pessina AC, Nussdorfer GG. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension. 1996;27:1153–9.

    Article  CAS  PubMed  Google Scholar 

  • Boulkroun S, Fernandes-Rosa FL, Zennaro MC. Molecular and cellular mechanisms of aldosterone producing adenoma development. Front Endocrinol (Lausanne). 2015;6:95.

    Google Scholar 

  • Braun-Menendez E, Page IH. Suggested revision of nomenclature – angiotensin. Science. 1958;127:242.

    Article  CAS  PubMed  Google Scholar 

  • Carey RM, Siragy HM, Felder RA. Physiological modulation of renal function by the renal dopaminergic system. J Auton Pharmacol. 1990;10 Suppl 1:s47–51.

    Article  CAS  PubMed  Google Scholar 

  • Clarke JG, Benjamin N, Larkin SW, Webb DJ, Davies GJ, Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol. 1989;257:H2033–5.

    CAS  PubMed  Google Scholar 

  • Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force. J Am Coll Cardiol. 2002;39:257–65.

    Article  PubMed  Google Scholar 

  • Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.

    Article  CAS  PubMed  Google Scholar 

  • den Ouden DT, Meinders AE. Vasopressin: physiology and clinical use in patients with vasodilatory shock: a review. Neth J Med. 2005;63:4–13.

    Google Scholar 

  • Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371:1921–6.

    Article  CAS  PubMed  Google Scholar 

  • Foulquier S, Steckelings UM, Unger T. Impact of the AT(2) receptor agonist C21 on blood pressure and beyond. Curr Hypertens Rep. 2012;14:403–9.

    Article  CAS  PubMed  Google Scholar 

  • Gaddam KK, Pimenta E, Husain S, Calhoun DA. Aldosterone and cardiovascular disease. Curr Probl Cardiol. 2009;34:51–84.

    Article  PubMed  Google Scholar 

  • Gavras H, Hatzinikolaou P, North WG, Bresnahan M, Gavras I. Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure. Hypertension. 1982;4:400–5.

    Article  CAS  PubMed  Google Scholar 

  • Goldstein DS. Stress, catecholamines and cardiovascular disease. New York: Oxford University Press; 1995.

    Google Scholar 

  • Goldstein DS, Eisenhofer G, McCarty R, editors. Catecholamines. Bridging basic science with clinical medicine. San Diego: Academic Press; 1998.

    Google Scholar 

  • Grunfeld JP, Eloy L. Glucocorticoids modulate vascular reactivity in the rat. Hypertension. 1987;10:608–18.

    Article  CAS  PubMed  Google Scholar 

  • Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989;86:2863–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]). Am J Cardiol. 1996;78:902–7.

    Article  Google Scholar 

  • Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R, RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:1499–507.

    Article  PubMed  Google Scholar 

  • Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665–75.

    Article  PubMed  Google Scholar 

  • Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–8.

    Article  CAS  PubMed  Google Scholar 

  • Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann Intern Med. 1994;120:227–37.

    Article  CAS  PubMed  Google Scholar 

  • McKinney CA, Fattah C, Loughrey CM, Milligan G, Nicklin SA. Angiotensin-(1–7) and angiotensin-(1–9): function in cardiac and vascular remodelling. Clin Sci (Lond). 2014;126:815–27.

    Article  CAS  Google Scholar 

  • Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I: natriuretic peptides. J Hypertens. 1992;10:907–12.

    CAS  PubMed  Google Scholar 

  • Padia SH, Carey RM. AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function. Pflugers Arch. 2013;465:99–110.

    Article  CAS  PubMed  Google Scholar 

  • Passos-Silva DG, Verano-Braga T, Santos RA. Angiotensin-(1–7): beyond the cardio-renal actions. Clin Sci (Lond). 2013;124:443–56.

    Article  CAS  Google Scholar 

  • Rocha R, Stier Jr CT. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001;12:308–14.

    Article  CAS  PubMed  Google Scholar 

  • Rossi G, Albertin G, Belloni A, Zanin L, Biasolo MA, Prayer-Galetti T, Bader M, Nussdorfer GG, Palu G, Pessina AC. Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex. J Clin Invest. 1994;94:1226–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rossitto G, Miotto D, Battistel M, Barbiero G, Maiolino G, Bisogni V, Sanga V, Rossi GP. Metoclopramide unmasks potentially misleading contralateral suppression in patients undergoing adrenal vein sampling for primary aldosteronism. J Hypertens. (2016) [Epub ahead of print]

    Google Scholar 

  • Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S. Multiple factors contribute to the pathogenesis of hypertension in cushing’s syndrome. J Clin Endocrinol Metab. 1986;62:275–9.

    Article  CAS  PubMed  Google Scholar 

  • Seccia TM, Caroccia B, Gioco F, Piazza M, Buccella V, Guidolin D, Guerzoni E, Montini B, Petrelli L, Pagnin E, Ravarotto V, Belloni AS, Calò LA, Rossi GP. Endothelin-1 drives epithelial-mesenchymal transition in hypertensive nephroangiosclerosis. J Am Heart Assoc. 2016;5(7):e003888. doi:10.1161/JAHA.116.003888.

    Article  PubMed  PubMed Central  Google Scholar 

  • Stewart PM. Mineralocorticoid hypertension. Lancet. 1999;353:1341–7.

    Article  CAS  PubMed  Google Scholar 

  • Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730–6. CONSENSUS Trial Study Group.

    Article  CAS  PubMed  Google Scholar 

  • Tigerstedt R, Bergmann PG. Niere und kreislauf. Skand Arch Physiol. 1898;8:223–7.

    Article  Google Scholar 

  • Whitworth JA, Williamson PM, Mangos G, Kelly JJ. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag. 2005;1:291–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:II2–10.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Massimo Mannelli .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Mannelli, M., Rossi, G.P., Vanderriele, PE., Parenti, G. (2018). The Endocrine Regulation of Blood Pressure. In: Belfiore, A., LeRoith, D. (eds) Principles of Endocrinology and Hormone Action. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-44675-2_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44675-2_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44674-5

  • Online ISBN: 978-3-319-44675-2

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics